08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

GI-5005: Additional Phase IIb data

GlobeImmune reported data from the 38 prior non-responders enrolled in an open-label Phase IIb trial showing that GI-5005 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) led to an SVR...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

GI-5005: Additional Phase IIb data

A retrospective analysis of 96 treatment-naïve patients from an open-label Phase IIb trial showed that GI-5005 plus SOC ( Copegus ribavirin and Pegasys peginterferon alfa-2a) led to improved ETR responses in all interleukin-28B (IL-28B;...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Clinical News

GI-5005: Additional Phase IIb data

Additional data from a Phase IIb trial in 140 patients with chronic HCV genotype 1 showed that significantly more patients receiving GI-5005 plus standard care with Copegus ribavirin and Pegasys peginterferon alfa-2a had...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

GI-5005: Additional Phase IIb data

Additional data from a prospective subgroup of treatment-naïve patients (n=102) in an open-label Phase IIb trial showed that GI-5005 plus pegylated interferon alpha-2a and ribavirin non-significantly increased response rate vs. pegylated interferon alpha-2a and ribavirin...
07:00 , Jun 15, 2009 |  BC Week In Review  |  Clinical News

PRO 206: Development discontinued

Progenics discontinued development of PRO 206, which was in preclinical development, in order to focus its resources on its second-generation HCV-entry inhibitor portfolio. The company expects to select a new development candidate from this portfolio...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

GI-5005: Interim Phase II data

Interim data from 117 treatment-naïve patients in an open-label Phase II trial showed that GI-5005 plus pegylated interferon and ribavirin non-significantly improved EVR to HCV RNA <25 IU/mL at week 12 vs. pegylated interferon and...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

GI-5005: Interim Phase II data

Interim data from 93 patients in an open-label Phase II trial showed GI-5005 plus pegylated interferon and ribavirin non-significantly improved rapid virologic response (RVR) to HCV RNA <25 IU/mL at week 4 compared to pegylated...
07:00 , May 26, 2008 |  BC Week In Review  |  Clinical News

GI-5005: Completed Phase II enrollment

GlobeImmune completed enrollment of 120 patients with chronic HCV genotype 1 infection in an open-label, international Phase II trial evaluating pegylated interferon plus ribavirin with or without subcutaneous GI-5005. GlobeImmune Inc., Louisville, Colo.   Product: GI-5005...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

GI-5005: Phase II started

GlobeImmune began an open-label, international Phase II trial in about 120 patients with chronic genotype 1 HCV infection to evaluate standard of care with or without GI-5005. GlobeImmune Inc., Louisville, Colo.   Product: GI-5005   Business:...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Clinical News

GI-5005: Interim Phase Ib data

Interim data from the double-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial in 42 evaluable patients showed that GI-5005 was safe and well tolerated. The treatment led to antigen specific cellular immune responses with broad epitope...